A summary of published research, not medical advice. See the Disclaimer.
Studies: every indexed trial and review on this topic, scored
BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide based on a fragment of a protein found in gastric juice. Almost everything known about it comes from rat and cell studies. As of 2026, published human data are three small uncontrolled pilot reports with 30 people in total: 16 in a knee pain chart review, 12 in a bladder pain pilot and 2 in an IV safety pilot [7][8][10][16].
Best-supported effect: None. No effect in humans reaches "Probably helps".
Most-cited weak claim: Faster healing of tendon, ligament and muscle injuries. Unknown (very weak evidence).
How we grade evidence · Last reviewed: October 2026
What you need to know
BPC-157 is not approved as a drug by the US FDA or other major regulators. No human trial has measured healing of any injury, and the healing claims rest on rat and cell studies, so the evidence is very weak. The human data come from three small reports in 30 people with no placebo group: 16 people asked about knee pain by phone, 12 women with interstitial cystitis, and an IV safety pilot in 2 adults. None of these reports recorded any adverse events. Reviews describe products sold outside regulation, with risks of contamination and unknown dose accuracy. No validated formulation or dosing regimen exists; the human reports used a single 10 mg bladder-wall injection and single IV infusions of 10 mg and 20 mg.
No effect of BPC-157 in people has a verdict of "Probably helps" or "Helps". A 2025 systematic review of the musculoskeletal literature included 36 studies; 35 were preclinical and one was clinical [3]. A 2025 review counted three human pilot studies in total [4].
| Claim | Verdict | What was measured | Studied in |
|---|---|---|---|
| Tendon, ligament and muscle healing | Unknown (very weak evidence) Rat and cell studies only, no human trial measured healing |
Measured | Rats and cell cultures only |
| Knee pain relief | Unknown (very weak evidence) Phone survey of 16 people, no placebo group |
Self-reported | 16 people, retrospective chart review |
| Interstitial cystitis (bladder pain) | Unknown (very weak evidence) Single early test in 12 women, no comparison group |
Self-reported | 12 women, uncontrolled pilot |
| Gut, brain, heart and eye protection | Unknown (very weak evidence) Injury studies in rodents only, no human studies |
Measured | Animal models only |
| Safe in humans | Unknown (very weak evidence) Early test by drip into a vein in 2 adults, too few and too short |
Measured | 2 adults, IV pilot |
Soft-tissue healing: Rat studies report faster tendon, ligament, muscle and bone healing [5], and in culture BPC-157 increases tendon cell outgrowth and migration [6]. No human trial has measured healing of any injury [3][4]. Unknown (very weak evidence). Animal and cell data only.
Knee pain: A clinic chart review contacted 16 people who had received knee injections of BPC-157, alone or with thymosin beta-4. 14 reported relief by phone survey, with no standard pain or function scale [7]. There was no control group and no blinding. Unknown (very weak evidence): no controlled trial.
Interstitial cystitis: 12 women whose symptoms had not responded to pentosan polysulfate received a single 10 mg injection into the bladder wall during cystoscopy. 10 reported full resolution on a global self-rating [8]. Without a control group, a placebo response can't be ruled out. Unknown (very weak evidence): no controlled trial.
Other organs: Reviews by the group that has done most of the animal research describe protective effects in rodent models of gut, heart, brain and eye injury [9]. None of these have been tested in people. Unknown (very weak evidence): animal data only.
Shown in humans
None found.
Shown only in animals or cells
Theory only
| Side effect | Verdict | How often vs placebo | Source | Studied in |
|---|---|---|---|---|
| Any adverse event in the three human pilot reports (30 people) | Unknown (very weak evidence) No harmful events recorded in 30 people, no placebo group |
Not reported (none reported; no placebo group) | [4][8][10][16] | 30 people |
| Changes in heart, liver, kidney, thyroid or blood glucose markers after IV infusion | Unknown (very weak evidence) No changes in lab test results in 2 people, no placebo group |
Not reported (no changes seen in 2 people; no placebo group) | [10] | 2 people |
| Harm from contamination or inaccurate dose in unregulated products | Unknown (not tested) Described in reviews as a risk, no rates reported |
Not reported | [1][3][11] |
The IV pilot gave 2 adults 10 mg and then 20 mg over two days, too few people and too short to establish safety [10]. A 2026 review of grey-market peptides says rigorous human safety data are scarce and there is potential for serious harm [11].
This lists what studies and labels report. A pharmacist or prescriber can say whether it applies to a specific person.
This lists what studies and labels report. A pharmacist or prescriber can say whether it applies to a specific person.
No interactions with drugs or supplements are documented in labels, case reports or interaction studies found for this article.
These are the amounts used in the studies. They are not recommendations.
Human reports used a 10 mg bladder-wall injection once [8], knee injections of unstated standardized dose [7], and single IV infusions of 10 mg and 20 mg [10]. None used a pharmaceutical-grade product [2]. Animal studies typically used microgram-per-kilogram doses that have not been translated to people [9]. In animals BPC-157 has a plasma half-life under 30 minutes, yet effects are reported to last hours to days. No validated formulation or dosing regimen exists [2].
BPC-157 is not approved as a drug by the US FDA or other major regulators, because there are no adequate clinical trials [1][3]. The human interstitial cystitis pilot used product from a 503A compounding pharmacy [8]. Sources disagree on sport rules: a 2025 systematic review describes it as banned in professional sports [3], while a 2025 review states it was temporarily banned by the World Anti-Doping Agency in 2022 and is not currently listed [1]. The current WADA Prohibited List is the authority on this point.